Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin - PubMed

Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin

J J Kirsi et al. Antimicrob Agents Chemother. 1984 Oct.

Abstract

The antiviral effects of selenazofurin (2-beta-D-ribofuranosylselenazole-4-carboxamide, selenazole), ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide), and 3-deazaguanosine (6-amino-1-beta-D-ribofuranosylimidazo-[4.5-C]pyridin-4(5H)-one) were investigated separately and in various combinations in an in vitro study. The combination interactions were evaluated at seven drug concentrations, graphically (isobolograms) or by using fractional inhibitory concentration indices against mumps, measles, parainfluenza virus type 3, vaccinia and herpes simplex virus type 2 viruses in Vero and HeLa cells. Selenazofurin in combination with ribavirin produced the greatest synergistic antiviral activity. However, the degree of synergy depended on the virus and cell line used. In contrast, selenazofurin combined with 3-deazaguanosine consistently yielded an indifferent or an antagonistic response, or both, whereas the ribavirin-3-deazaguanosine interaction was additive against the same viruses. Single-drug cytotoxicity was minimal for the cytostatic agents selenazofurin and ribavirin but was markedly higher for cytocidal 3-deazaguanosine, as determined by relative plating efficiency after drug exposure. The drug combinations did not significantly increase cytotoxicity (they were only additive) when used on uninfected cells. Therefore, the enhanced antiviral activities of the drug combinations (shown to be synergistic) were due to specific effects against viral replication. These results indicated that in Vero and HeLa cells (i) the combination of selenazofurin and ribavirin produced an enhanced antiviral effect, thus requiring smaller amounts of drug to cause the same antiviral effect relative to a single compound; (ii) selenazofurin when compared with ribavirin and 3-deazaguanosine appeared to have a somewhat different mode of antiviral action; (iii) 3-deazaguanosine combined with selenazofurin was an unsuitable antiviral combination; and (iv) the antiviral activity of 3-deazaguanosine appeared to be due largely to its general overall cytotoxic effect.

Similar articles

• Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

  Huggins JW, Robins RK, Canonico PG. Huggins JW, et al. Antimicrob Agents Chemother. 1984 Oct;26(4):476-80. doi: 10.1128/AAC.26.4.476. Antimicrob Agents Chemother. 1984. PMID: 6151377 Free PMC article.

• Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

  Kirsi JJ, North JA, McKernan PA, Murray BK, Canonico PG, Huggins JW, Srivastava PC, Robins RK. Kirsi JJ, et al. Antimicrob Agents Chemother. 1983 Sep;24(3):353-61. doi: 10.1128/AAC.24.3.353. Antimicrob Agents Chemother. 1983. PMID: 6615611 Free PMC article.

• The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin.

  Robins RK, Revankar GR, McKernan PA, Murray BK, Kirsi JJ, North JA. Robins RK, et al. Adv Enzyme Regul. 1985;24:29-43. doi: 10.1016/0065-2571(85)90068-8. Adv Enzyme Regul. 1985. PMID: 2872781

• Molecular mechanisms of action of ribavirin.

  Patterson JL, Fernandez-Larsson R. Patterson JL, et al. Rev Infect Dis. 1990 Nov-Dec;12(6):1139-46. doi: 10.1093/clinids/12.6.1139. Rev Infect Dis. 1990. PMID: 2267489 Review.

• Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance.

  Beaucourt S, Vignuzzi M. Beaucourt S, et al. Curr Opin Virol. 2014 Oct;8:10-5. doi: 10.1016/j.coviro.2014.04.011. Epub 2014 May 19. Curr Opin Virol. 2014. PMID: 24846716 Free PMC article. Review.

Cited by

• Effects of selenazofurin and ribavirin and their 5'-triphosphates on replicative functions of influenza A and B viruses.

  Wray SK, Smith RH, Gilbert BE, Knight V. Wray SK, et al. Antimicrob Agents Chemother. 1986 Jan;29(1):67-72. doi: 10.1128/AAC.29.1.67. Antimicrob Agents Chemother. 1986. PMID: 3729336 Free PMC article.

• Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

  Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N, Smith EP, Takeuchi K, Senda T, Kofuji S, Sasaki AT. Naffouje R, et al. Cancers (Basel). 2019 Sep 11;11(9):1346. doi: 10.3390/cancers11091346. Cancers (Basel). 2019. PMID: 31514446 Free PMC article. Review.

• Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections.

  Baker RO, Bray M, Huggins JW. Baker RO, et al. Antiviral Res. 2003 Jan;57(1-2):13-23. doi: 10.1016/s0166-3542(02)00196-1. Antiviral Res. 2003. PMID: 12615299 Free PMC article.

• Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses.

  Huggins JW, Robins RK, Canonico PG. Huggins JW, et al. Antimicrob Agents Chemother. 1984 Oct;26(4):476-80. doi: 10.1128/AAC.26.4.476. Antimicrob Agents Chemother. 1984. PMID: 6151377 Free PMC article.

• Picornavirus inhibitors.

  Carrasco L. Carrasco L. Pharmacol Ther. 1994;64(2):215-90. doi: 10.1016/0163-7258(94)90040-x. Pharmacol Ther. 1994. PMID: 7533301 Free PMC article. Review.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central